155 related articles for article (PubMed ID: 33539397)
1. Survival in untreated hepatocellular carcinoma: A national cohort study.
Kim YA; Kang D; Moon H; Sinn D; Kang M; Woo SM; Chang YJ; Park B; Kong SY; Guallar E; Shin SY; Gwak G; Back JH; Lee ES; Cho J
PLoS One; 2021; 16(2):e0246143. PubMed ID: 33539397
[TBL] [Abstract][Full Text] [Related]
2. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
3. Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma.
Peters NA; Javed AA; He J; Wolfgang CL; Weiss MJ
J Surg Res; 2017 Apr; 210():253-260. PubMed ID: 28457336
[TBL] [Abstract][Full Text] [Related]
4. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study.
Lee DW; Yim HJ; Seo YS; Na SK; Kim SY; Suh SJ; Hyun JJ; Jung SW; Jung YK; Koo JS; Kim JH; Yeon JE; Lee SW; Byun KS; Um SH
Liver Int; 2019 Jun; 39(6):1109-1119. PubMed ID: 30972935
[TBL] [Abstract][Full Text] [Related]
5. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.
Wu CY; Chen YJ; Ho HJ; Hsu YC; Kuo KN; Wu MS; Lin JT
JAMA; 2012 Nov; 308(18):1906-14. PubMed ID: 23162861
[TBL] [Abstract][Full Text] [Related]
6. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
7. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.
Lee JH; Kim HY; Kim YJ; Yoon JH; Chung JW; Lee HS
J Gastroenterol Hepatol; 2015 Apr; 30(4):696-705. PubMed ID: 25250761
[TBL] [Abstract][Full Text] [Related]
8. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.
Seo YS; Kim YJ; Kim MS; Suh KS; Kim SB; Han CJ; Kim YJ; Jang WI; Kang SH; Tchoe HJ; Park CM; Jo AJ; Kim HJ; Choi JA; Choi HJ; Polak MN; Ko MJ
Medicine (Baltimore); 2016 Apr; 95(17):e3527. PubMed ID: 27124061
[TBL] [Abstract][Full Text] [Related]
9. Does low income effects 5-year mortality of hepatocellular carcinoma patients?
Kim DJ; Yoo JW; Chang JW; Yamashita T; Park EC; Han KT; Kim SJ; Kim SJ
Int J Equity Health; 2021 Sep; 20(1):151. PubMed ID: 34465351
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
[TBL] [Abstract][Full Text] [Related]
11. Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia.
Nguyen VT; Amin J; Law MG; Dore GJ
J Gastroenterol Hepatol; 2009 Mar; 24(3):436-42. PubMed ID: 19175834
[TBL] [Abstract][Full Text] [Related]
12. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
13. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
15. Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival.
Yan M; Ha J; Aguilar M; Liu B; Frenette CT; Bhuket T; Wong RJ
J Clin Gastroenterol; 2017 Apr; 51(4):378-383. PubMed ID: 27380460
[TBL] [Abstract][Full Text] [Related]
16. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.
Rich NE; Hester C; Odewole M; Murphy CC; Parikh ND; Marrero JA; Yopp AC; Singal AG
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):551-559.e1. PubMed ID: 29859983
[TBL] [Abstract][Full Text] [Related]
18. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.
El-Serag HB; Davila JA
Hepatology; 2004 Mar; 39(3):798-803. PubMed ID: 14999699
[TBL] [Abstract][Full Text] [Related]
19. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database?
Liu H; Cen D; Yu Y; Wang Y; Liang X; Lin H; Cai X
BMC Cancer; 2018 Nov; 18(1):1125. PubMed ID: 30445928
[TBL] [Abstract][Full Text] [Related]
20. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area.
Kang HY; Shin HD; Kim SB; Song IH
Clin Res Hepatol Gastroenterol; 2012 Aug; 36(4):357-64. PubMed ID: 22326248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
